RN
RNTX.US Rein Therapeutics Inc
- Market cap
- USD 30.7M
- P/E
- -
- P/B
- 4.46x
- ROE
- -304.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is RNTX.US undervalued?
Graham numberThe Graham number of Rein Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Rein Therapeutics Inc fundamental analysis
No fundamental analysis for Rein Therapeutics Inc yet.
Rein Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Rein Therapeutics Inc
Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleur…
Full company profileRein Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Rein Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | - | - | - | -63.0K | -1.00K | - |
| Operating Income | -20.5K | -26.6K | -27.6K | -16.3K | -65.1M | -21.9M | -24.4M |
| EBITDA | 143K | 94.8K | 142K | 104K | -28.0M | -50.6M | -24.8M |
| Net Income | -21.2K | -26.2K | -27.3K | -15.7K | -62.9M | -49.9M | -23.7M |
| EPS | 0.00 | -0.01 | -0.01 | 0.00 | -3.51 | -1.96 | -0.27 |
| Balance Sheet | |||||||
| Total Assets | 16.3M | 48.5M | 22.0M | 106M | 69.2M | 24.2M | 59.4M |
| Total Liabilities | 4.18M | 4.58M | 3.38M | 99.1M | 14.8M | 7.24M | 6.66M |
| Shareholders' Equity | 12.2M | 43.9M | 18.6M | 6.89M | 54.4M | 16.9M | 7.77M |
| Cash & Short-term Investments | 13.8M | 45.9M | 21.2M | 17.3M | 12.9M | 3.22M | 35.5M |
| Total Debt | 387K | 162K | 33.0K | 48.0K | - | - | - |
| Cash Flow | |||||||
| Operating Cash Flow | -20.5M | -23.8M | -24.9M | -19.8M | -22.3M | -19.4M | -25.8M |
| Capital Expenditure | 5.00K | 157K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -20.5M | -23.9M | -24.9M | -19.8M | -22.3M | -19.4M | -25.8M |
| Ratios | |||||||
| ROE | -0.2% | -0.1% | -0.1% | -0.2% | -115.6% | -294.8% | -304.7% |
| ROA | -0.1% | -0.1% | -0.1% | 0.0% | -90.8% | -206.4% | -39.8% |
| Debt to Equity | 0.03x | 0.00x | 0.00x | 0.01x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Rein Therapeutics Inc dividends
Rein Therapeutics Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:20 on Nov 11, 2022.
Who owns Rein Therapeutics Inc
- Insiders 5.02%
- Institutions 52.78%
- Public & others 42.20%
- Shares outstanding 86.3M
- Free float 66.1M
Top funds holding RNTX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 2.52M | 2.92% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 366K | 0.42% | -0.38% | Sep 2026 |
| Fidelity Series Total Market Index | 106K | 0.12% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 101K | 0.12% | 0.00% | Sep 2026 |
| iShares Micro-Cap ETF | 79.0K | 0.09% | 0.00% | Oct 2026 |
| Fidelity Nasdaq Composite ETF | 76.6K | 0.09% | 0.00% | Oct 2026 |
| Vanguard U.S. Eq Idx £ Acc | 51.0K | 0.06% | +299.18% | Sep 2026 |
| Vanguard Balanced Index Inv | 43.4K | 0.05% | 0.00% | Sep 2026 |
| 1290 VT Micro Cap K | 5.74K | 0.01% | 0.00% | Sep 2026 |
Top institutions holding RNTX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Voss Capital LLC | 5.26M | 6.10% | +19.91% | Jun 2026 |
| Cable Car Capital LLC | 5.20M | 6.02% | +1,136.90% | Jun 2026 |
| ADAR1 Capital Management LLC | 4.50M | 5.22% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 3.38M | 3.92% | +238.29% | Jun 2026 |
| BIOS CAPITAL MANAGEMENT, LP | 2.98M | 3.46% | +50.44% | Jun 2026 |
| Ikarian Capital, LLC | 2.95M | 3.42% | 0.00% | Jun 2026 |
| Great Point Partners LLC | 2.58M | 2.98% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 2.44M | 2.83% | 0.00% | Jun 2026 |
| Velan Capital Investment Management LP | 1.70M | 1.97% | 0.00% | Jun 2026 |
| Prosight Management, LP | 1.66M | 1.92% | +50.93% | Sep 2026 |
| RIMA MANAGEMENT, LLC | 1.23M | 1.43% | +433.10% | Jun 2026 |
| Bleichroeder LP | 1.00M | 1.16% | 0.00% | Jun 2026 |
| BOOTHBAY FUND MANAGEMENT, LLC | 889K | 1.03% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 733K | 0.85% | +112.70% | Jun 2026 |
| University Of Texas Investment Mgmt Co | 512K | 0.59% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 383K | 0.44% | +147.56% | Jun 2026 |
| State Street Corp | 380K | 0.44% | +400.11% | Jun 2026 |
| Empery Asset Management, LP | 371K | 0.43% | 0.00% | Jun 2026 |
| Palogic Value Management LP | 360K | 0.42% | +100.00% | Jun 2026 |
| Sigma Planning Corp | 354K | 0.41% | +1.43% | Jun 2026 |
Rein Therapeutics Inc company profile
- Company name
- Rein Therapeutics Inc
- Ticker
- RNTX.US
- Exchange
- USA Stocks
- Listed since
- Mar 12, 1986
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 10
- Fiscal year end
- December
- Address
- 12407 N. Mopac Expy., Austin, TX, United States, 78758
- Phone
- 737 802 1989
- Website
- reintx.com
About Rein Therapeutics Inc
Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications; and LTI-05, an epithelial sodium channel, which is in preclinical trial phase for the treatment of cystic fibrosis. The company was formerly known as Aileron Therapeutics, Inc. and changed its name to Rein Therapeutics Inc. in February 2007. The company was incorporated in 2001 and is headquartered in Austin, Texas.
Rein Therapeutics Inc management
5- Dr. James Brian Windsor Ph.D.CEO, President & Director · born 1966
- Mr. Timothy M. Cunningham CPA, M.B.A.Interim CFO & Principal Accounting Officer · born 1962
- Dr. Cory M. Hogaboam Ph.D.Chief Scientific Officer
- Ms. Jennifer FaigleCounsel
- Mr. Ron ChenVP of Finance and Corporate Controller